685 related articles for article (PubMed ID: 18032540)
1. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
[TBL] [Abstract][Full Text] [Related]
2. What predicts obesity in patients with rheumatoid arthritis? An investigation of the interactions between lifestyle and inflammation.
Stavropoulos-Kalinoglou A; Metsios GS; Smith JP; Panoulas VF; Douglas KM; Jamurtas AZ; Koutedakis Y; Kitas GD
Int J Obes (Lond); 2010 Feb; 34(2):295-301. PubMed ID: 19859075
[TBL] [Abstract][Full Text] [Related]
3. New resting energy expenditure prediction equations for patients with rheumatoid arthritis.
Metsios GS; Stavropoulos-Kalinoglou A; Panoulas VF; Koutedakis Y; Nevill AM; Douglas KM; Kita M; Kitas GD
Rheumatology (Oxford); 2008 Apr; 47(4):500-6. PubMed ID: 18304942
[TBL] [Abstract][Full Text] [Related]
4. Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor.
Engvall IL; Elkan AC; Tengstrand B; Cederholm T; Brismar K; Hafstrom I
Scand J Rheumatol; 2008; 37(5):321-8. PubMed ID: 18666027
[TBL] [Abstract][Full Text] [Related]
5. Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis.
Syngle A; Vohra K; Kaur L; Sharma S
Scand J Rheumatol; 2009; 38(1):15-22. PubMed ID: 18766955
[TBL] [Abstract][Full Text] [Related]
6. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P
J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
[TBL] [Abstract][Full Text] [Related]
7. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
[TBL] [Abstract][Full Text] [Related]
8. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
[TBL] [Abstract][Full Text] [Related]
9. Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres.
Smith N; Gadsby K; Butt S; Carruthers D; Deeming A; Ledingham J; Fletcher M; Mulherin D; Roskell S; Kay L; Nicholl K; Cooper R; Worsley A; Deighton C
Rheumatology (Oxford); 2007 Oct; 46(10):1557-9. PubMed ID: 17666440
[TBL] [Abstract][Full Text] [Related]
10. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Park MC; Chung SJ; Park YB; Lee SK
Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
[TBL] [Abstract][Full Text] [Related]
11. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
[TBL] [Abstract][Full Text] [Related]
12. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
[TBL] [Abstract][Full Text] [Related]
13. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
La DT; Collins CE; Yang HT; Migone TS; Stohl W
Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
[TBL] [Abstract][Full Text] [Related]
15. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor.
Roubenoff R; Roubenoff RA; Ward LM; Holland SM; Hellmann DB
J Rheumatol; 1992 Oct; 19(10):1505-10. PubMed ID: 1464859
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-alpha production is associated with less body cell mass in women with rheumatoid arthritis.
Walsmith J; Abad L; Kehayias J; Roubenoff R
J Rheumatol; 2004 Jan; 31(1):23-9. PubMed ID: 14705214
[TBL] [Abstract][Full Text] [Related]
17. Resting energy expenditure and nutritional status in children with juvenile rheumatoid arthritis.
Knops N; Wulffraat N; Lodder S; Houwen R; de Meer K
J Rheumatol; 1999 Sep; 26(9):2039-43. PubMed ID: 10493689
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
[TBL] [Abstract][Full Text] [Related]
19. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis.
Radovits BJ; Fransen J; Eijsbouts A; van Riel PL; Laan RF
Rheumatology (Oxford); 2009 Aug; 48(8):906-10. PubMed ID: 19478038
[TBL] [Abstract][Full Text] [Related]
20. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy.
Mäki-Petäjä KM; Hall FC; Booth AD; Wallace SM; Yasmin ; Bearcroft PW; Harish S; Furlong A; McEniery CM; Brown J; Wilkinson IB
Circulation; 2006 Sep; 114(11):1185-92. PubMed ID: 16952987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
